Key Points
- CEO Thane Wettig bought 2,700 shares of FibroGen on Nov. 17 at an average price of $9.10 (totaling $24,570), increasing his direct stake to 24,939 shares — a 12.14% rise — as disclosed in an SEC Form 4 filing.
- FibroGen shares opened at $8.70 with a market cap of about $35.2M and a negative P/E; the company reported Q3 EPS of ($1.61), which beat analysts' ($4.01) estimate by $2.40 while revenue ($1.08M) missed estimates, and analysts' consensus is a "Hold" with an average target of $43.00.
FibroGen, Inc (NASDAQ:FGEN - Get Free Report) CEO Thane Wettig bought 2,700 shares of the company's stock in a transaction that occurred on Monday, November 17th. The shares were bought at an average cost of $9.10 per share, for a total transaction of $24,570.00. Following the transaction, the chief executive officer directly owned 24,939 shares of the company's stock, valued at $226,944.90. This trade represents a 12.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Thane Wettig also recently made the following trade(s):
- On Thursday, November 13th, Thane Wettig bought 1,000 shares of FibroGen stock. The stock was bought at an average price of $9.18 per share, with a total value of $9,180.00.
FibroGen Stock Up 0.1%
FibroGen stock opened at $8.70 on Tuesday. The business has a 50 day moving average price of $11.14 and a two-hundred day moving average price of $9.07. The stock has a market cap of $35.19 million, a price-to-earnings ratio of -22.89 and a beta of 0.75. FibroGen, Inc has a 12 month low of $4.85 and a 12 month high of $21.94.
FibroGen (NASDAQ:FGEN - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.61) earnings per share for the quarter, topping analysts' consensus estimates of ($4.01) by $2.40. The business had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.64 million. On average, analysts expect that FibroGen, Inc will post -0.8 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on FGEN shares. HC Wainwright restated a "buy" rating and set a $43.00 target price on shares of FibroGen in a research report on Wednesday, September 24th. Weiss Ratings reiterated a "sell (e+)" rating on shares of FibroGen in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised FibroGen from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $43.00.
Get Our Latest Analysis on FGEN
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in FibroGen by 3.5% in the third quarter. Vanguard Group Inc. now owns 184,244 shares of the biopharmaceutical company's stock valued at $2,257,000 after purchasing an additional 6,204 shares during the last quarter. Armistice Capital LLC boosted its holdings in FibroGen by 25.0% during the first quarter. Armistice Capital LLC now owns 8,500,000 shares of the biopharmaceutical company's stock worth $2,634,000 after buying an additional 1,700,000 shares during the last quarter. Two Sigma Investments LP grew its position in shares of FibroGen by 185.0% during the 3rd quarter. Two Sigma Investments LP now owns 40,218 shares of the biopharmaceutical company's stock worth $493,000 after buying an additional 26,107 shares during the period. Citadel Advisors LLC acquired a new position in shares of FibroGen during the 3rd quarter worth about $288,000. Finally, Squarepoint Ops LLC bought a new stake in shares of FibroGen in the 3rd quarter valued at about $201,000. 72.71% of the stock is currently owned by institutional investors.
FibroGen Company Profile
(
Get Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
